What are the early signs of detection of the coronavirus
Pro Research Analysisby 
Searched over 200M research papers
Early Signs of Detection of the Coronavirus
Clinical Symptoms: Fever, Cough, and Fatigue
One of the earliest signs of COVID-19 infection includes clinical symptoms such as fever, dry cough, and fatigue. These symptoms were observed in a significant number of patients in various studies. For instance, fever was reported in 87% of patients, dry cough in 60%, and fatigue in 39%2. Additionally, other symptoms like myalgia, weakness, and dyspnea have also been noted as early indicators of the disease4.
Imaging Findings: Ground-Glass Opacities and Patchy Lesions
High-resolution computed tomography (HRCT) and chest CT scans are crucial for early detection of COVID-19. Common early imaging findings include ground-glass opacities (GGO) and patchy lesions. In one study, 83.3% of patients had ground-glass opacities, and 66.7% had ground-glass nodules1. Another study found that 60% of patients had GGO, with or without consolidation, primarily in the peripheral zones of the lungs2. These imaging features are essential for identifying early-stage COVID-19, even when clinical symptoms are mild or atypical1 2 7.
Laboratory Findings: Elevated C-Reactive Protein and Lymphocyte Count
Laboratory tests also play a significant role in early detection. Elevated high-sensitivity C-reactive protein (CRP) levels were found in 99% of patients, indicating an inflammatory response2. Additionally, a normal or reduced lymphocyte count was observed in 60% of patients, which can help differentiate COVID-19 from other infections2.
Humoral Response: IgM and IgA Antibodies
The body's humoral response, particularly the production of IgM and IgA antibodies, can aid in early detection. IgM and IgA antibodies were detectable within a median of 5 days after symptom onset, with positive rates of 85.4% and 92.7%, respectively3. Combining IgM ELISA assays with PCR tests significantly improves the detection rate, making it a valuable tool for early diagnosis3.
Chemosensory Dysfunction: Loss of Smell and Taste
Loss of smell (anosmia) and taste (ageusia) are early and sometimes subclinical symptoms of COVID-19. These symptoms can appear before more common symptoms like fever and cough, making them useful for early screening and isolation of cases5.
Molecular and Saliva Testing: RT-qPCR and Saliva Samples
Molecular tests, such as quantitative real-time reverse-transcription PCR (RT-qPCR), are essential for early detection. These tests target specific regions of the viral genome and can detect the virus even in low quantities6. Saliva samples have also proven to be a reliable non-invasive specimen for detecting the virus, with a high detection rate of 91.7% in patients10. This method is particularly useful for monitoring and infection control.
Conclusion
Early detection of COVID-19 relies on a combination of clinical symptoms, imaging findings, laboratory tests, and molecular diagnostics. Recognizing early signs such as fever, dry cough, fatigue, ground-glass opacities in CT scans, elevated CRP levels, and the presence of IgM and IgA antibodies can significantly aid in the timely diagnosis and management of the disease. Additionally, the loss of smell and taste, along with advanced molecular and saliva testing, provide valuable tools for early detection and containment of the virus.
Sources and full results
Most relevant research papers on this topic
Pulmonary High-Resolution Computed Tomography (HRCT) Findings of Patients with Early-Stage Coronavirus Disease 2019 (COVID-19) in Hangzhou, China
Early-stage COVID-19 imaging manifestations are relatively mild, and some patients may have nontypical findings, leading to missed diagnoses.
Observational Study
Rigorous JournalEarly Clinical and CT Manifestations of Coronavirus Disease 2019 (COVID-19) Pneumonia.
Early clinical and laboratory findings of COVID-19 pneumonia include low to midgrade fever, dry cough, and fatigue, with normal WBC count, reduced lymphocyte count, and elevated high-sensitivity C-reactive protein level.
Observational Study
Highly CitedProfiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)
The humoral response to SARS-CoV-2 can aid in diagnosing COVID-19, including subclinical cases, with higher detection efficiency when combined with qPCR.
Observational StudyHighly Cited[Early detection and disease assessment of patients with novel coronavirus pneumonia].
Early detection of novel coronavirus pneumonia can be improved by evaluating severity using fever, cough, myalgia, weakness, dyspnea, and imaging.
Association of chemosensory dysfunction and COVID‐19 in patients presenting with influenza‐like symptoms
COVID-19 is associated with early loss of smell and taste, which may aid in early screening and isolation of cases.
Highly CitedMolecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia
The developed assays can rapidly detect the novel coronavirus (2019-nCoV) in human samples, enabling early identification of infected patients.
In Vitro StudyHighly CitedCoronavirus disease 2019: initial chest CT findings
Multiple ground-glass opacities with consolidations in the lungs are the primary CT characteristic of COVID-19, and increased CT scores may indicate disease progression in the progressive stage.
Observational StudyRigorous JournalHighly CitedDiagnostic methods and potential portable biosensors for coronavirus disease 2019
Antigen-based detection methods are needed for early and asymptomatic COVID-19 detection, and portable biosensors and AI-assisted diagnosis are promising.
Highly CitedAdvance Warning Methodologies for COVID-19 Using Chest X-Ray Images
The Convolutional Support Estimator Network (CSEN) and DenseNet-121 networks effectively detect early-stage COVID-19 from chest X-ray images, with the CSEN achieving over 97% sensitivity and DenseNet-121 reaching 95% sensitivity and 99.74% specificity.
Consistent Detection of 2019 Novel Coronavirus in Saliva
Saliva is a promising noninvasive specimen for diagnosis, monitoring, and infection control in patients with 2019 novel coronavirus infection.
Observational StudyHighly Cited